Fetalix
A regenerative, fetal-inspired solution for treating low back pain through a minimally invasive approach.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
€15.0k | Support Program | ||
| Total Funding | 000k | ||
| EUR | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | 60 % | - | 1928 % |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
We provide the first regenerative fetal-inspired solution to treat low back pain through a minimally-invasive application.
Our developed and patented natural biomaterial is obtained from a mammalian fetal source offering unique regenerative properties.
This injectable and off-the-shelf material provides veterinaries and orthopaedic surgeons a new and preventive treatment for intervertebral disc degeneration, eliminating the need for surgical procedures and reoperations, while reducing intervention time by 90% and hospital stays by 70%.
Production is simple, safe, affordable and scalable and promotes circular economy by creating value from animal waste.